MedTrace Logo

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

NCT00243984 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of topiramate compared to placebo in the treatment of obesity in metabolic syndrome. Secondary objectives include topiramate and weight loss effects on lipid levels, HbA1C, insulin resistance, and blood pressure.

Conditions

  • Metabolic Syndrome X
  • Diabetes Mellitus, Type 2

Interventions

DRUG

topiramate

Sponsors & Collaborators

  • Cleveland Clinic Akron General

    collaborator OTHER

  • Forum Health

    collaborator INDUSTRY

  • Aultman Health Foundation

    collaborator OTHER

  • St. Elizabeth Health Center

    collaborator UNKNOWN

  • Mercy Medical Center

    collaborator OTHER

  • Northeastern Ohio Universities College of Medicine

    lead OTHER

Principal Investigators

  • Frederick Whittier, MD · Northeastern Ohio Universities College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243984 on ClinicalTrials.gov